Bakteriyofaj Tedavisi
Bakterilerin paraziti olan bakteriyofajlar, keşfedildikten sonra bakteriyel hastalıklara karşı tedavide kullanılmaya başlanmış ancak antibiyotiklerin keşfiyle, özellikle Batı ülkelerinde, faj tedavisine ilgi azalmıştır. Günümüzde antibiyotiklere karşı bakteri direncinin oluşması önemli bir sorun haline gelmiştir. Bu durum, bakteriyel hastalıkların tedavisinde ve proflakside alternatif arayışları zorunlu kılmıştır ve faj tedavisi yeniden ele alınmıştır.
___
- 1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM, (2011). Phage
treatment of human infections. Landes Bioscience Journals,
bacteriophage,1, 66-85.
http://www.landesbioscience.com/journals/bacteriophage/article/
15845
- 2. Barrow P, Lovell M, Berchieri AO Jr, (1998). Use of lytic
bacteriophage for control of experimental Escherichia coli
septicemia and meningitis in chickens and calves. Clinical
and Diagnostic Laboratory Immunology. 5, p. 294-98.
- 3. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, B. Powell,
Carlton R, Merril CR, (2002). Bacteriophage therapy
rescues mice bacteremic from a clinical isolate of vancomycin
resistant Enterococcus faecium. Infect Immun.70,
204-210.
- 4. Bruttin A, Brussow H, (2005). Human volunteers receiving
Escherichia coli phage T4 orally: a safety test of phage
therapy. Antimicrob Agents. 49, 2874-2878
- 5. Carrillo CL, Abedon ST, (2011). Pros and cons of phage
therapy. Bacteriophage, 1, 111-14 http://www.landesbioscience.
com/journals/bacteriophage/LocCarrilloBP1-2.pdf
- 6. Chanishvili N, Chanishvili T, Tediashvili M, Barrow PA,
(2001). Phages and their application against drug resistant
bacteria, J Chem Technol Biotechnol.76, 689-699.
- 7. Clark JR, March JB, (2006). Bacteriophages and biotechnology:
vaccines, gene therapy and antibacterials. Trends in
Biotechnology. 24, 212-218.
- 8. Connerton PL, Loc CarrilloCM, Swift C, Dillon E, Scott A,
Rees CED, Dodd CER, Frost J, Connerton IF, (2004). Longitudinal
study of Campylobacter jejuni bacteriophages and
their hosts from broiler chickens. Appl environ microbiol.
70, 3877-3883.
- 9. Fortier LC, Moineau S, (2009). Phage production and maintenance
of stocks, including expected stock lifetimes.
Martha R. J. Clokie, Andrew M. Kropinski (eds.), Bacteriophages:
Methods and Protocols, Volume 1: Isolation,
characterization, and interactions, humana press, a part of
springer science,business media. 501, 203-219
- 10. Fortuna W, Międzybrodzki R, Dąbrowska B, Dąbrowska W,
Górski A, (2008). Bacteriophage therapy in children: Facts
and prospects. Med Sci monit. 14, 126-132.
- 11. Gill JJ, Hyman P, (2010). Phage choice, isolation, and preparation
for phage therapy. 11, 2-14
- 12. Gill JJ, Pacan JC, Carson ME, Leslie KE, Griffiths MW,
Sabour PM, (2006a). Efficacy and pharmacokinetics of
bacteriophage therapy in treatment of subclinical Staphylococcus
aureus mastitis in lactating dairy cattle. Antimicrob
agents chemother. 50, 2912-2918
- 13. Gill JJ, Sabour PM, Leslie KE, Griffiths W, (2006b). Bovine
whey proteins inhibit the interaction of Staphylococcus aureus
and bacteriophage K J. Appl Microbiol. 101, 377-386
14. Goodridge LD, (2010). Designing phage therapeutics, 11,
15-27.
- 15. Gürgün V, Halkman K, (1990). Mikrobiyolojide sayım yöntemleri.
Gıda Teknolojisi Derneği. Yayın no 7. http://www.
mikrobiyoloji.org/TR/Genel/BelgeGoster.aspx?F6E10F88
92433CFFAAF6AA849816B2EF10F86F55954CBB47
- 16. Hanlon GW, (2007). Bacteriophages: an appraisal of their
role in the treatment of bacterial infections. IJAA. 30, 118-
128.
- 17. Haq UI, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I,
(2012). Bacteriophages and their implications on future
biotechnology: a review. Virology Journal. (9), 1-9.
- 18. Hawkins C, Harper D, Burch D, Anggard E, Soothill J,
(2010). Topical treatment of Pseudomonas aeruginosa otitis
of dogs with a bacteriophage mixture: A before/after clinical
trial. Veterinary microbiology. (146) 309-313.
- 19. Hudson JA, Billington C, Carey-Smith G, Greening G,
(2005). Bacteriophages as biocontrol agents in food. Journal
of Food Protection, 68, 426-437
- 20. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM,
(2003). Evaluation of aerosol spray and intramuscular injection
of bacteriophage to treat an Escherichia coli respiratory
infection. Poultry science. 82, 1108-1112.
- 21. Huff WE, Huff GR, Rath NC, Balog JM, Xie H, Moore
PA, Donoghue AM, (2002). Prevention of Escherichia coli
respiratory infection in Broiler chickens with bacteriophage
(SPR02). Poultry Science. 81, 437-441.
- 22. Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM,
(2004). Therapeutic efficacy of bacteriophage and Baytril
(Enrofloxacin) individually and in combination to treat Colibacillosis
in broilers. Poultry science. 83, 1944-1947.
- 23. Johnson RP, Gyles CL, Huff WE, Ojha S, Huff GR, Rath
NC, Donoghue AM, (2008). Bacteriophages for prophylaxis
and therapy in cattle, poultry and pigs. Cambridge
University Press ISSN 1466-2523, Animal Health Research
Reviews. 9, 201-215
- 24. Kramberger P, Honour RC, Herman RE, Smrekara F, Peterka
M, (2010). Purification of the Staphylococcus aureus
bacteriophages VDX-10 on methacrylate monoliths, 166,
60-64
- 25. Letarov AV, Golomidova AK, Tarasyan KK, (2010). Ecological
basis for rational phage therapy. Acta naturae. 2,
60-72.
- 26. Levin BR, Bull JJ, (2004). Population and evolutionary dynamics
of phage therapy. Nature Reviews Microbiology. 2,
166-173.
- 27. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara
T, Shuin T, Shen T, Jin Z, Fujimoto S, Nasimuzzaman MD,
Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A,
Imai S, (2003). Experimental protection of mice against
lethal Staphylococcus aureus infection by novel bacteriophage
φ MR11. JID. 2003, 187, 613-624.
- 28. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo
S, Adhya S, (1996). Proc. Longcirculating bacteriophage
as antibacterial agents. Natl Acad Sci USA. 93, 3188-3192.
- 29. Międzybrodzki R, Fortuna W, Dąbrowska BW, Górski A,
(2007). Phage therapy of staphylococcal infections (including
MRSA) may be less expensive than antibiotic treatment.
Postepy Hig Med Dosw. 61, 461-465.
- 30. Nakai T, Park SC, (2002). Bacteriophage therapy of infectious
diseases in aquaculture. Research in Microbiology.
153, 13-18.
- 31. O’Flaherty S, Ross RP, Coffey A, (2009). Bacteriophage
and their lysins for elimination of infectious bacteria.
FEMS. 33, 801-819.
- 32. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ,
(2007). Novel alternatives to antibiotics: bacteriophages,
bacterial cell wall hydrolases, and antimicrobial peptides.
J Appl Microbiol. 104, 1-13.
- 33. Park SC, Shimamura I, Fukunaga M, Mori K-I, Nakai T,
(2000). Isolation of bacteriophages specific to a fish pathogen,
Pseudomonas plecoglossicida, as a candidate for disease
control. APPL environ microbiol. 66, 1416-1422.
- 34. Pirnay JP, De Vos D, Verbeken G, Merabishvili M, Chanishvili
N, Vaneechoutte M, Laire MZG, Lavigne R, Huys I,
Mooter GV, Buckling A, Debarbieux L, Pouillot F, Azeredo
J, Kutter E, Dublanchet A, Górski A, Adamia R, (2011).
The phage therapy paradigm: prêtàporter or surmesure?
Springer Science Pharm Res. 28, 934-937.
- 35. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF, (2011).
Recent advances in bacteriophage therapy: how delivery
routes, formulation, concentration and timing influence the
success of phage therapy. Journal of Pharmacy and Pharmacology.
63, 1253-1264.
- 36. Sheng H, Knecht HJ, Kudva IT, Hovde CJ, (2006). Application
of bacteriophages to control intestinal Escherichia coli
O157:H7 levels in ruminants. APPL Environ Microbiol. 72,
5359-5366.
- 37. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-
Krukowska A, (1987). Results of bacteriophage
treatment of suppurative bacterial infections in the years
1981–1986. Arch Immunol Ther Ex. 35: 569-583.
- 38. Smith HW, Huggins MB, (1982). Successful treatment
of experimental Escherichia coli ınfections in mice using
phage: its general superiority over antibiotics. J gen microbiol.
128, 307-318.
- 39. Smrekar F, Ciringer M, Peterka M, Podgornik A, Strancar
A, (2008). Purification and concentration of bacteriophage
T4 using monolithic chromatographic supports. J Chromatogr
AnalytTechnol Biomed LifeSci. 861, 177-180.
- 40. Soothill J, Hawkins C, Anggård E, Harper D, (2004). Therapeutic
use of bacteriophages. The Lancet Infectious Diseases.
4, 544-545.
- 41. Sulakvelidze A, Alavidze Z, Morris Jr JG, (2001). Bacteriophage
therapy. ASM Antimicrob Agents Chemother. 45,
649-659.
- 42. Summers WC, (2001). Bacteriophage therapy. Annu Rev
Microbiol. 55, 437-451.
- 43. Ustaçelebi Ş, Okuyan M, Odabaşıoğlu N, (1968). T4 R mutant
bakteriyofajları ile serolojik deneyler ve normal insan
serumlarının faj enfeksiyonunda stimülan etkisi. Mikrobiyoloji
Bülteni. 4, 131-141.
- 44. Weber-Dabrowska B, Mulczyk M, Gorski A, (2003). Bacteriophages
as an efficient therapy for antibioticresistant septicemia
in man. Transplant Proc. 35, 1385-1386
- 45. Weber-Dabrowska B, Mulczyk M, Gorski A, (2001). Bacterophage
therapy for infections in cancer patients. Clin Applied
Immunol Rev. 1, 131-134.
- 46. Yoshida K, Nasau Y, Shitami N, Toyoda H, Takemura H,
Oomori K, (2009). A novel convenient method for high
bacteriophage titer assay. Oxford University Press, Nucleic
Acids Symposium Series. 53, 315-316.
- 46. Lu TK, Koeris MS, (2011). The next generation of bacteriophage
therapy. Current opinion in microbiology. 14,
524–31.